Eli Lilly and Company (NYSE:LLY ) 2025 Wells Fargo Healthcare Conference September 5, 2025 9:30 AM EDT Company Participants Patrik Jonsson - Executive VP & President of Lilly International Mike Czapar
Eli Lilly (LLY 0.56%) is typically a market outperformer, but it has had a challenging year so far. Besides general market volatility, the company has dealt with clinical setbacks, lower-than-expected
While many dividend stocks are viewed as slow-growing investments, this isn't always the case. Right now, investment bank analysts up and down Wall Street are bullish for a pair of dividend-paying sto
Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Diseases Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Disease
The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be present

Where Will Eli Lilly Be in 3 Years?

04:25am, Thursday, 04'th Sep 2025
Eli Lilly (LLY 0.15%) stock has soared in the triple digits over the past three years thanks to one particular product line: its weight-loss drugs. Lilly is the maker of tirzepatide, sold under the na

Eli Lilly's Stock Fall Is An Opportunity

12:09am, Thursday, 04'th Sep 2025
I am bullish on Eli Lilly, despite recent underperformance and Orforglipron's clinical results falling short of high expectations. Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes,
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Insider Watch: 3 CEOs Buying the Dip

12:31pm, Wednesday, 03'rd Sep 2025
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture.
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLY
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
September has garnered a reputation as the worst month for stock market performance, supported by compelling historical data.
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE